Fexofenadine Decreases Sensitivity to and Montelukast Improves Recovery from Inhaled Mannitol

Publisher Website
Google Scholar
Abstract
We studied, separately, the effects of the histamine antagonist, fexofenadine hydrochloride, and the leukotriene antagonist, montelukast sodium, and their placebos on airway sensitivity to and recovery from inhaled mannitol in subjects with asthma. Two 180-mg doses of fexofenadine were taken over 14 h, and three 10-mg doses of montelukast over 36 h, with the last dose 5 h before challenge. Fexofenadine reduced sensitivity to mannitol and the PD15 was (mean [95% confidence interval] 138 [95, 201]) mg versus placebo (51 [25, 106] mg) (p < 0.001). The final percent reduction in FEV1 with fexofenadine was 20.8 ± 5.4% and not different from placebo (20.1 ± 5.3%) (p = 0.7); however, recovery was slower with fexofenadine compared with placebo (p < 0.001). By contrast, montelukast had no effect on sensitivity to mannitol and the PD15 was 71 [36, 144] mg versus placebo (87 [51, 148] mg (p = 0.35). The total dose of mannitol delivered and the final percent reduction in FEV1 with montelukast were 171 ± 142 mg and 21 ± 4% and for placebo were 182 ± 144 mg and 20 ± 5% (p = 0.35, p = 0.59, respectively). However, recovery of FEV1 to baseline was faster with montelukast, with the area under the percent reduction FEV1-versus-time curve reduced (220 ± 121% change · min) compared with placebo (513 ± 182% change · min) (p < 0.001). We conclude that whereas histamine is important for the initial airway response, leukotrienes are important in sustaining the airway response to inhaled mannitol.